LLY Vs NVO: Foundayo Beats Novo’s Oral Semaglutide On Weight Loss, Blood Sugar In New Finding
Eli Lilly (LLY) was in the spotlight on Tuesday after a new analysis suggested that its once-daily Foundayo pill could deliver greater weight loss and reductions in blood sugar levels than Novo’s (NVO) higher-dose oral semaglutide in adults with type 2 diabetes.LLY shares edged 0.3% higher in pre-m…